Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T15:52:02.718Z.
Calculation as of: 2026-10-06T15:52:02.718Z.
Quote observation: 2026-10-06T15:48:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b39d0c73cbdfa69f0b7c8f40e573a317b01c7cc2fd28b7d8d8bae27d2fbb310
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$82.26M
Operating Cash Flow Yield
N/A
TTM Avg
0.15%
3Y Avg
0.15%
5Y Avg
0.15%
Market Cap
$82.75M
Operating Cash Flow Yield
N/A
TTM Avg
0.91%
3Y Avg
0.91%
5Y Avg
0.91%
Market Cap
$83.04M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.98M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.55M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.01M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENSAR Inc (LNSR) | $82.29M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $82.26M | N/A | 0.15% | 0.15% | 0.15% |
| Nutriband Inc. (NTRB)vs › | $80.47M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.75M | N/A | 0.91% | 0.91% | 0.91% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $79.98M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $85.55M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.17M | N/A | 5.92% | 6.70% | 6.29% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
